<div id="readability-page-1">ASC37 has shown to have an average observed half-life of around 17 days in head-to-head non-human primate studies, which is 7 times longer than retatrutide. This indicates its potential for once-monthly subcutaneous dosing in humans. Additionally, ASC37 exhibited approximately 5-, 4-, and 4-fold greater in vitro activity compared to other substances.</div>

<p>ASC37 has shown to have an average observed half-life of around 17 days in head-to-head non-human primate studies, which is 7 times longer than retatrutide. This indicates its potential for once-monthly subcutaneous dosing in humans. Additionally, ASC37 exhibited approximately 5-, 4-, and 4-fold greater in vitro activity compared to other substances.</p>

Unusual Whales

ALPS Medical Breakthrough

Direxion Daily LLY Bull 2X Shares

Ark Genomic Revolution ETF

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

VG Health

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

iShares Biotechnology ETF

Eli Lilly

Health Care Select Sector SPDR

iShares US Pharma

Ascletis chooses ASC37, a once-monthly subcutaneously administered peptide agonist, with 17-day half-life, for clinical development.